Skip to main content
    L

    LENZ Therapeutics Inc (LENZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.50
    -0.32 (-8.38%)

    Market Cap: $120.03M

    Last updated: Nov 17, 2026 at 4:43 PM ET

    LENZ Therapeutics Inc (LENZ) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    LENZ Therapeutics (LENZ) has a market cap of $120.03M and an enterprise value of $89.47M. It kept -1134.97% of revenue as net income over the last 12 months. Its share count is up 10.09% from a year earlier.

    Total Valuation

    Enterprise value is 25.46% below the market cap, as cash exceeds debt.

    Market Cap$120.03M
    Enterprise Value$89.47M
    Latest price (Nov 17, 2026)$3.50

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.15% in the quarter ended Sep 30, 2026 and grew 7.53% a year over 2 years.

    Shares Outstanding31.42M
    Shares Change (YoY)+10.09%
    Shares Change (QoQ)+0.15%
    Share Count Growth (2Y CAGR)+7.53%

    Valuation Ratios

    Sales and book value multiples are 8.9x and 0.6x.

    P/S Ratio8.9x
    Forward P/S8.3x
    P/B Ratio0.6x

    Price Statistics

    The stock is down 86.33% over 52 weeks and trades 5.91% below its 50-day average.

    Beta (1Y)2.17
    52-Week Change-86.33%
    1-Month Change+6.06%
    3-Month Change-28.86%
    6-Month Change-47.37%
    5-Year Change-96.58%
    Total Return (1Y)-86.33%
    Total Return (3Y CAGR)-33.15%
    Total Return (5Y CAGR)-42.78%
    Return vs SPY (1Y)-98.71%
    Max Drawdown (1Y)-90.58%
    Max Drawdown (3Y)-93.86%
    Sharpe Ratio (1Y)-2.42
    Correlation with SPY (1Y)0.35
    50-Day Average$3.72
    200-Day Average$7.12
    52-Week Range$2.80 to $32.13
    RSI (14 Days)46.7
    Average Volume (20 Days)1.23M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 11.66x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio11.66x
    Quick Ratio11.39x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -73.06% and return on assets is -66.88% over the last 12 months.

    Return on Equity (ROE)-73.06%
    Return on Assets (ROA)-66.88%
    ROA (5Y Average)-39.68%
    ROIC (5Y Average)-32.14%
    Asset Turnover0.06x
    Inventory Turnover0.50x
    Receivables Turnover18.24x
    Cash Conversion Cycle-249 days

    Scores

    LENZ has an Altman Z-Score of 0.28, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score0.28
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $12.36M over the last 12 months is down 29.64% from the 12 months before.

    Revenue$12.36M
    Revenue Growth (YoY)-29.64%
    Gross Profit$10.13M
    Operating Income-$149.69M
    Pretax Income-$140.27M
    Net Income-$140.27M
    Reported EPS (TTM)-$4.49

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 91.54% of the $209.75M in total assets.

    Cash and Equivalents$30.55M
    Total Debt$0
    Net Cash$30.55M
    Net Cash Per Share$0.97
    Working Capital$189.15M
    Shareholder Equity$192.00M
    Book Value Per Share$6.11
    Total Assets$209.75M
    Total Liabilities$17.75M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$127.63M
    FCF Per Share-$4.06
    Depreciation and Amortization$1.53M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1211.17%.

    Gross Margin81.97%
    Operating Margin-1211.17%
    Pretax Margin-1134.93%
    Net Margin-1134.97%

    Dividends and Yields

    LENZ does not pay a dividend.

    Buyback Yield-111.24%
    Shareholder Yield-111.24%

    Stock Splits

    The last split was a 1-for-7 reverse split on Mar 22, 2024.

    Last Split DateMar 22, 2024
    Split TypeReverse split
    Split Ratio1:7

    Analyst Forecast

    Consensus estimates put revenue growth at 30.74% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+30.74%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About LENZ

    What is LENZ's market cap?

    LENZ Therapeutics has a market cap of $120.03M. Its enterprise value, which adds debt and subtracts cash, is $89.47M.

    How many shares of LENZ are outstanding?

    LENZ Therapeutics has 31.42M shares outstanding. The count is up 10.09% from a year earlier.

    Does LENZ pay a dividend?

    No. LENZ Therapeutics does not pay a dividend.

    How much debt does LENZ have?

    LENZ Therapeutics has $0 of total debt and $30.55M of cash and equivalents, a net cash position of $30.55M.